Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00372294
Other study ID # 8415
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received September 5, 2006
Last updated July 28, 2008
Start date July 2005
Est. completion date November 2008

Study information

Verified date June 2008
Source hahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin & Dexamethasone.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date November 2008
Est. primary completion date August 2008
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with Toxoplasmic chorioretinitis

- Location of the lesion within zone I of the retina or a lesion greater than 2DD with 3+-4+ vitreous inflammation in zone II or III

- No allergic history to the used drugs

- No any other diseases

Exclusion Criteria:

- Any allergic reaction to the used medications

- One eyed patients

- Partially treated patients

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
pyrimethamine-sulfadiazine + prednisolone
Administration of pyrimethamine-sulfadiazine + prednisolone
Clindamycin+Dexamethasone
Intravitreal injection of Clindamycin+Dexamethasone

Locations

Country Name City State
Iran, Islamic Republic of Ophthalmic Research Center Tehran

Sponsors (1)

Lead Sponsor Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

See also
  Status Clinical Trial Phase
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Recruiting NCT04245072 - Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis N/A
Recruiting NCT05335746 - Ocular Changes in Vitiligo Patients on Therapy
Withdrawn NCT01151462 - Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.